These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6796795)

  • 21. Analysis of deprenyl metabolites in the rat brain using HPLC-ES-MS.
    Kalász H; Bartók T; Szöko E; Haberle D; Kiss JP; Hennings EC; Magyar K; Fürst S
    Curr Med Chem; 1999 Apr; 6(4):271-8. PubMed ID: 10101213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
    Cohen G; Pasik P; Cohen B; Leist A; Mytilineou C; Yahr MD
    Eur J Pharmacol; 1984 Oct; 106(1):209-10. PubMed ID: 6442232
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain.
    Fowler JS; Wolf AP; MacGregor RR; Dewey SL; Logan J; Schlyer DJ; Langstrom B
    J Neurochem; 1988 Nov; 51(5):1524-34. PubMed ID: 3139834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The aphrodisiac effect of low doses of (-) deprenyl in male rats.
    Yen TT; Dalló J; Knoll J
    Pol J Pharmacol Pharm; 1982; 34(5-6):303-8. PubMed ID: 6821215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.
    Zsilla G; Barbaccia ML; Gandolfi O; Knoll J; Costa E
    Eur J Pharmacol; 1983 Apr; 89(1-2):111-7. PubMed ID: 6305680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of beta-phenylethylamine concentration on its substrate specificity for type A and type B monoamine oxidase.
    Suzuki O; Katsumata Y; Oya M; Matsumoto I
    Biochem Pharmacol; 1979 Mar; 28(6):953-6. PubMed ID: 454494
    [No Abstract]   [Full Text] [Related]  

  • 28. [Properties of the binding of 1-deprenil (Jumex) to melanin pigment].
    Báthory G; Szüts T; Magyar K
    Acta Pharm Hung; 1989; 59 Suppl 1():69-74. PubMed ID: 2518280
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization and identification of covalently bound flavoproteins in rat liver mitochondria by prelabeling of their flavin moiety.
    Sato M; Ohishi N; Yagi K
    J Biochem; 1984 Aug; 96(2):553-62. PubMed ID: 6438072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
    Fowler CJ; Mantle TJ; Tipton KF
    Biochem Pharmacol; 1982 Nov; 31(22):3555-61. PubMed ID: 6817759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoamine oxidase of rat skeletal muscle: substrate specificity and half-life.
    Kwatra MM; Sourkes TL
    Life Sci; 1980 Dec; 27(24):2327-31. PubMed ID: 7207021
    [No Abstract]   [Full Text] [Related]  

  • 34. Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine.
    Tábi T; Magyar K; Szöko E
    Electrophoresis; 2003 Aug; 24(15):2665-73. PubMed ID: 12900880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [3H]tryptamine binding sites are not identical to monoamine oxidase in rat brain.
    Perry DC; Grimm LJ; Kettler KG; Kellar KJ
    J Neurochem; 1988 Nov; 51(5):1535-40. PubMed ID: 3139835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity.
    Haberle D; Szökö E; Halász AS; Magyar K
    J Neural Transm (Vienna); 2001; 108(11):1239-47. PubMed ID: 11768624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo.
    Timár J
    Acta Physiol Hung; 1989; 74(3-4):259-66. PubMed ID: 2517980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of 2-phenylethylamine binding after monoamine oxidase inhibition in rat brain.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    Eur J Pharmacol; 1992 Jan; 210(2):189-93. PubMed ID: 1601056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential postnatal development of monoamine oxidases A and B in the blood-brain barrier of the rat.
    Kalaria RN; Harik SI
    J Neurochem; 1987 Nov; 49(5):1589-94. PubMed ID: 3117975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats.
    Timár J; Knoll B
    Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):50-60. PubMed ID: 3083795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.